CC Diagnostics
CC Diagnostics is a Netherlands-based medical technology company developing the Methica CC Kit, a PCR-based molecular diagnostic using novel epigenetic biomarkers for cervical cancer screening. It targets healthcare systems and clinical laboratories, and is currently pre-commercial pending regulatory approval.
- Company typePrivate
- Founded2016
- HeadquartersGroningen, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What CC Diagnostics does
CC Diagnostics is a Netherlands-based medical technology company, founded in 2016 and headquartered in Groningen, that is developing the Methica CC Kit — a PCR-based reagent assay for cervical cancer screening. The kit uses novel epigenetic (DNA methylation) biomarkers originally identified at the University Medical Centre Groningen (UMCG) by founders Bea Wisman and Ed Schuuring, and is positioned as a triage test alongside primary HPV testing. Clinical validation completed in July 2024 using samples from the Dutch National Screening Program reported 97% sensitivity for cancer detection, a 21% absolute improvement over Pap smear without loss of specificity, 6x less hands-on time, and throughput of up to 94 samples per run. The product is currently in development and not yet available for clinical use, with regulatory approval and commercialization identified as the next milestones.
The company's go-to-market is enterprise field sales targeting two primary buyer segments: healthcare systems and payers (including government screening programs such as the Dutch National Screening Program) seeking lower treatment costs via earlier detection, and clinical laboratories and clinics seeking automated, high-throughput molecular workflows to replace manual, subjective Pap smear analysis. Distribution is direct to healthcare institutions via clinical and product specialists. Ancillary segments (women/patients, including via self-sampling) are referenced as downstream beneficiaries rather than direct purchasers. The company has begun preparing for US market entry through the Cedars-Sinai HealthTech Mini-Accelerator (February 2025) alongside NBSO Los Angeles and ScaleNL, and is engaged with regional Dutch stakeholders including Gemeente Groningen, Provincie Groningen, Northern Netherlands Alliance (SNN), and RVO.
The core team consists of eight members: CEO Ronald Vos (30 years of life sciences/diagnostics experience at Thermo Fisher, Luminex, and Millipore), CMO Nutte van Belzen (involved since company inception, leading product development and clinical validation), CSO Jolien de Waard (PhD from the UMCG biomarker research group), plus Product Specialist, Junior Product Specialist, QA Manager, and Financial Controller roles. Seven additional advisors cover regulatory affairs, production, M&A, investment, and scientific matters. Disclosed investors include Carduso Capital, with Koos Koops serving as advisor.
CC Diagnostics firmographics
Firmographics- Name
- CC Diagnostics
- Legal name
- CC Diagnostics
- Website
- https://cc-diagnostics.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CC Diagnostics is a Netherlands-based medical technology company developing the Methica CC Kit, a PCR-based molecular diagnostic using novel epigenetic biomarkers for cervical cancer screening. It targets healthcare systems and clinical laboratories, and is currently pre-commercial pending regulatory approval.
- Ownership category
- akta.pro rank
CC Diagnostics industry classification
Industry- Product category
- Molecular Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
- akta.pro secondary industries
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
Keywords
Where CC Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Groningen
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
CC Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Methica CC Kit Sales: PCR reagent kit for cervical cancer screening. Product in development, not yet commercially available. Revenue expected from kit sales to healthcare systems and laboratories following regulatory approval.
- Healthcare Cost Savings: Economic value proposition emphasizing cost savings for healthcare systems - up to €700M in potential savings through earlier cancer detection reducing treatment costs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Product in development - no commercial pricing available |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
CC Diagnostics product offering
Product offeringCore offering
CC Diagnostics is developing the Methica CC Kit, a PCR-based reagent kit for cervical cancer screening that uses proprietary epigenetic (DNA methylation) biomarkers derived from research at University Medical Centre Groningen (UMCG). The kit targets clinical laboratories performing cervical cancer screening as a follow-up triage test after primary HPV testing, offering 97% sensitivity in clinical validation studies, 6x less hands-on time than Pap smear, and compatibility with laboratory automation workflows. The product is currently in development with regulatory approval and commercialization as next milestones.
Product overview
CC Diagnostics is developing a single product - the Methica CC Kit - a PCR-based reagent kit for cervical cancer screening. The technology leverages novel epigenetic biomarkers for early cancer detection, offering 97% sensitivity and 6x less hands-on time compared to traditional Pap smear methods. The product is in development and has completed clinical validation studies.
Differentiator
Problem solved
Functional benefit
Brands
- Methica CC: PCR-based reagent kit for cervical cancer screening using novel epigenetic biomarkers, providing 97% sensitivity for cancer detection.
Products and services
- Methica CC Kit A PCR-based reagent kit for cervical cancer screening that uses novel proprietary epigenetic (DNA methylation) biomarkers. It targets clinical laboratories and healthcare systems as a triage test following primary HPV testing, provides early detection of cervical cancer with 97% sensitivity in clinical validation studies, can test up to 94 samples simultaneously, and is designed for compatibility with laboratory automation workflows. The product is currently in development and not available for clinical use, with regulatory approval and commercialization as next milestones.
Quantifiable outcome
- 97% sensitivity for cancer detection
- +5 more outcomes
Companies that use CC Diagnostics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
CC Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CC Diagnostics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, major, strategic and supporting.
- University Medical Centre Groningen (UMCG)coreResearch collaboration where the epigenetic biomarker technology was originally developed. Bea Wisman and Ed Schuuring from UMCG are inventors of the core technology. UMCG participated in clinical validation study.
- Cedars-Sinai AcceleratormajorCollaborative partner through HealthTech Mini-Accelerator program for Dutch startups. Provides mentorship network and US market entry preparation.
- ScaleNLmajorDutch startup support organization collaborating on the HealthTech Mini-Accelerator program with Cedars-Sinai and NBSO Los Angeles.
- NBSO Los AngelesmajorNetherlands Business Support Office in Los Angeles, collaborating on US market entry program.
- IQ ProductsstrategicCEO Joost Schuitemaker serves as advisor on production and product development, bringing industry experience from both research and manufacturer's perspective.
- Tech4EvasupportingGlobal Femtech accelerator program supporting women's health innovation. CC Diagnostics mentioned as part of ecosystem.
- EIT HealthsupportingEuropean health innovation network supporting healthcare startups. CC Diagnostics mentioned as part of ecosystem.
- Jeroen Bosch ZiekenhuisstrategicClinical partner hospital participating in multi-center clinical validation studies.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
CC Diagnostics competitors and assessment
Company assessmentBroad incumbents
- QIAGEN: Global molecular diagnostics and sample technologies leader with PCR-based HPV testing and a broad cervical cancer screening portfolio. Directly comparable as a molecular diagnostic reagent/kit provider using PCR chemistry for oncology indications.
- Hologic: Women-focused diagnostics company best known for ThinPrep Pap Test and Aptima HPV assays. Directly competes in cervical cancer screening using both cytology and molecular methods; key reference customer for hospital labs CC Diagnostics targets.
- Roche Diagnostics: Cobas HPV test is one of the most widely deployed primary HPV screening assays globally. Comparable as a dominant molecular cervical screening vendor with established regulatory and reimbursement infrastructure.
- Cepheid (Danaher): PCR-based GeneXpert platform with Xpert HPV test, operating in centralized and near-patient molecular diagnostics labs. Comparable PCR workflow, automation angle, and cervical cancer focus.
- Abbott Molecular: RealTime and Alinity m molecular diagnostic systems with HPV screening assays and broad oncology menu. Comparable as an established PCR-based cervical screening reagent provider.
- BD (Becton Dickinson) Molecular Diagnostics: Provides Onclarity HPV assay and BD MAX system for molecular cervical cancer screening. Comparable workflow (automated PCR) and target buyer (clinical labs).
Direct peers
- oncgnostics GmbH: German molecular diagnostics company developing GynTect, an epigenetic biomarker-based cervical cancer triage test using methylation markers on a similar platform. Direct competitor targeting the same HPV-positive triage use case with the same technology modality.
- PreTect AS (Arctic Bioscience): Develops molecular cervical cancer screening assays (PreTect HPV Proofer, PreTect See) targeting E6/E7 mRNA biomarkers. Direct peer in molecular cervical screening with a triage positioning analogous to Methica CC.
- Seegene: Korean molecular diagnostics company with high-throughput, syndromic PCR assays including Anyplex HPV-related tests. Directly comparable as a PCR-based molecular oncology/cervical screening reagent provider with strong automation/throughput positioning.
Emerging players
- Volition Diagnostics: Epigenetic diagnostics company using Nu.Q nucleosome methylation biomarker platform across oncology and other indications. Comparable emerging peer leveraging epigenetic biomarkers in cancer detection, though broader in indication than CC Diagnostics.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
CC Diagnostics social profiles
Digital presenceCC Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
CC Diagnostics leadership team
Management profileNumber of profiles
Profiles7 records
CC Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CC Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CC Diagnostics
What does CC Diagnostics do?
CC Diagnostics is developing the Methica CC Kit, a PCR-based reagent kit for cervical cancer screening that uses proprietary epigenetic (DNA methylation) biomarkers derived from research at University Medical Centre Groningen (UMCG). The kit targets clinical laboratories performing cervical cancer screening as a follow-up triage test after primary HPV testing, offering 97% sensitivity in clinical validation studies, 6x less hands-on time than Pap smear, and compatibility with laboratory automation workflows. The product is currently in development with regulatory approval and commercialization as next milestones.
Is CC Diagnostics a public or private company?
CC Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was CC Diagnostics founded?
CC Diagnostics was founded in 2016. It employs 1 to 10 people.
Where is CC Diagnostics based?
CC Diagnostics is headquartered in Groningen, Netherlands, in the Europe region.
How does CC Diagnostics make money?
Two revenue lines are on record. Methica CC Kit Sales are the primary driver. The others are healthcare Cost Savings.
Who are CC Diagnostics's main competitors?
Broad incumbents on record are QIAGEN, Hologic, Roche Diagnostics, Cepheid (Danaher), Abbott Molecular and BD (Becton Dickinson) Molecular Diagnostics. Direct peers are oncgnostics GmbH, PreTect AS (Arctic Bioscience) and Seegene. Volition Diagnostics is listed as an emerging player.
Does CC Diagnostics have an API?
No public API is recorded for CC Diagnostics.
What industry is CC Diagnostics in?
CC Diagnostics's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 325413 and its SIC code is 2835.